In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top ...

The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...

Shares of Replimune Group Inc. (NASDAQ:REPL) plunged 36% in premarket trading after a report revealed new details about the ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no ...

RP1’s “infinitely scalable” platform can synchronously connect hundreds of millions of users to one another in a real-time, persistent virtual world, without the need for sharding, said Mann.

RP1 plus nivolumab demonstrated robust response rates in anti-PD-1 failed melanoma patients, with an objective response rate of 32.9% and a complete response rate of 15.0%.

RP1 won “ Innovation of the Year ” WebXR Awards 2023 by the Poly Awards. Learn more at rp1.com. All trademarks and registered trademarks previously cited are hereby recognized and acknowledged.

The RP1 is a chip that puts nearly all of the Pi’s external interfaces onto a PCIe peripheral, but in reality we think it’s more than that.